Clinical Review

Guideline for primary care management of headache in adults

Werner J. Becker MD FRCP(C)  Ted Findlay DO CCFP  Carmen Moga MD MSc
N. Ann Scott PhD  Christa Harstall MHS A  Paul Taenzer PhD RPsysch

Abstract

Objective To increase the use of evidence-informed approaches to diagnosis, investigation, and treatment of headache for patients in primary care.

Quality of evidence A comprehensive search was conducted for relevant guidelines and systematic reviews published between January 2000 and May 2011. The guidelines were critically appraised using the AGREE (Appraisal of Guidelines for Research and Evaluation) tool, and the 6 highest-quality guidelines were used as seed guidelines for the guideline adaptation process.

Main message A multidisciplinary guideline development group of primary care providers and other specialists crafted 91 specific recommendations using a consensus process. The recommendations cover diagnosis, investigation, and management of migraine, tension-type, medication-overuse, and cluster headache.

Conclusion A clinical practice guideline for the Canadian health care context was created using a guideline adaptation process to assist multidisciplinary primary care practitioners in providing evidence-informed care for patients with headache.

EDITOR’S KEY POINTS

• Headache is one of the most common reasons patients seek help from family physicians, and treatment is often suboptimal. This article outlines the development and key recommendations of the clinical practice guideline created by a multidisciplinary guideline development group to assist Canadian primary care practitioners with providing evidence-informed care for patients with headache.

• Migraine, which is historically underdiagnosed, is by far the most common headache type in patients seeking help for headache. Neuroimaging, sinus or cervical spine x-ray scans, and electroencephalograms are not recommended for the routine assessment of patients with headache: history and physical and neurologic examination findings are usually sufficient to make a diagnosis. Comprehensive migraine therapy includes management of lifestyle factors and triggers, acute and prophylactic medications, and migraine self-management strategies. Treatment of tension-type, cluster, and medication-overuse headache is also outlined.

Headache is one of the most common reasons patients seek help from family physicians. The estimated lifetime prevalence of headache is 66%: 14% to 16% for migraine, 46% to 78% for tension-type headache, and 0.1% to 0.3% for cluster headache. In Canada, at least 2.6 million adult women and nearly 1 million men experience migraine. About 90% of migraine sufferers report moderate to severe pain, with 75% reporting impaired function and 33% requiring bed rest during an attack. The economic effects of headache are also substantial. It is estimated that headache accounts for 20% of work absences.

Vast quantities of over-the-counter medications are taken for headache disorders, and treatment is often suboptimal. Although most migraine sufferers use acute treatment to relieve their headaches, a substantial number of people who might benefit from prophylactic therapy do not receive it—more than 1 in 4 migraineurs are candidates for preventive therapy.

Better information and education for patients and health professionals is essential to improving management of headache in primary care, which should lead to prompt diagnosis and more effective treatment. To help address this, a consortium of organizations and clinicians from Alberta developed the Guideline for Primary Care Management of Headache in Adults.

This article has been peer reviewed. Can Fam Physician 2015;61:670-9

La traduction en français de cet article se trouve à www.cfp.ca dans la table des matières du numéro d’août 2015 à la page e353.
Scope
The Alberta guideline is intended to assist any primary care practitioner responsible for the assessment and management of headaches in adults. The guideline’s main focus is primary headache disorders (eg, migraine, tension-type, and cluster headache) and medication-overuse headache. Some advice is also provided for the diagnosis and investigation of secondary headache disorders and the management of cervicogenic headache and temporomandibular joint disorder. The guideline will be helpful to a range of primary health care professionals, including family physicians, physical therapists, occupational therapists, nurses, nurse practitioners, pharmacists, psychologists, and chiropractors.

Development
Leadership. The lead organizations involved in developing the guideline were Toward Optimized Practice (TOP), which develops and disseminates primary care guidelines in Alberta, and the Institute of Health Economics (IHE). Three multidisciplinary committees were formed to coordinate guideline production:
• The Steering Committee provided operational oversight.
• The Guideline Development Group (GDG) formulated the recommendations and comprised 9 family physicians, 2 neurologists, an osteopathic physician, a chiropractor, 2 physical therapists, an occupational therapist, a nurse, a pharmacist, 2 psychologists, and a health technology assessment specialist.
• The Advisory Committee advised the Steering Committee on strategic matters and included representatives from the Alberta College of Family Physicians, the Alberta College of Physicians and Surgeons, Alberta Health Services, Alberta Health, the Pain Society of Alberta, and a chronic pain patient advocacy group, as well as experts in guideline development and dissemination.

A research team of health technology assessment researchers with methodologic expertise from the IHE assisted the Steering Committee and GDG.11

Literature review. The Alberta guideline was developed using a guideline adaptation process, which takes advantage of existing high-quality guidelines and allows guideline developers to modify the recommendations from these seed guidelines to meet the needs of the local health care setting.12 Guideline adaptation is a popular alternative to de novo guideline development owing to the need to reduce duplication and constrain costs in the creation of evidence-informed guidelines.13-16

The research team collaborated with experienced medical librarians to systematically search for existing clinical practice guidelines (CPGs) published between January 2000 and May 2011. The search identified 64 guidelines, 18 of which were deemed relevant after application of specific selection criteria developed by the research team and content experts from the GDG.11

The quality of the guidelines was appraised independently by 2 reviewers (C.M. and N.A.S.) using the AGREE (Appraisal of Guidelines for Research and Evaluation) instrument,16,17 which was modified to reduce the subjectivity of the item scoring and to enable the differentiation of good- from poor-quality guidelines.18 Although an updated AGREE tool was published in May 2009,19,20 the research team elected to use the original instrument in order to maintain consistency with previous guidelines produced by TOP and the IHE. Of the 18 potentially eligible guidelines, 6 were scored as good quality and were chosen as seed guidelines.

Two reviewers (C.M. and N.A.S.) extracted the following information into standardized evidence tables: the source of the guideline, the recommendations, the number and types of studies used to create the recommendations (eg, 5 randomized controlled trials), and the strength of the recommendations. A total of 187 recommendations were tabulated. Discordant recommendations were highlighted in the tables.

Practice recommendations. The GDG reviewed the 6 seed guidelines, their companion documents, and the evidence tables during 13 half-day meetings: 1 face-to-face meeting and 12 Web conferences using WebEx (Cisco Systems Inc), which allowed all GDG members to view documents simultaneously and to register their preferences using an online voting system. The 2 GDG cochairs (W.J.B. and P.T.) led all sessions and conducted roundtable discussions for every recommendation to ensure that each GDG member had a voice in the process.

In some cases, the GDG requested additional evidence to resolve uncertainties or disagreements regarding interpretation of the evidence from the seed guidelines or when new interventions were considered that had not been included in the seed guidelines. These “parking lot” requests triggered examination of individual research studies cited by the seed guidelines, as well as additional systematic reviews on headache disorders identified by a supplementary search for literature published between January 2000 and October 2010.11 The parking lot items were referred for further analysis to ad hoc GDG subcommittees that included one or both cochairs, one IHE researcher, and at least one volunteer from the GDG with expertise in the relevant area. Consensus-based decisions made by the subcommittees were then presented to the GDG for final approval. Occasionally new recommendations were generated from parking lot item discussions. A special GDG subcommittee, which included a neuroradiologist, was created for the diagnostic imaging recommendations. The 23-month guideline development process resulted in 91 draft recommendations.
Each recommendation in the Alberta guideline came from 1 or more seed guidelines, was based on evidence from systematic reviews or quasi-systematic reviews, or was created by the GDG members, based on their collective professional opinion and an analysis of relevant evidence. The original wording of the recommendations was retained whenever possible, and designations were used (e.g., SR for systematic review, CS for case series) to maintain a link to the evidence cited by the seed guidelines. The principles outlined in the GuideLine Implementability Appraisal tool, which is designed for appraising the implementability of CPGs, were used as a guide when crafting the recommendations. Standardized definitions for the types of recommendations made in the Alberta CPG were constructed from the evidence-rating scales used by the seed guidelines. The recommendations were categorized as do when the evidence supported the intervention, do not do when the evidence suggested the intervention was ineffective or harmful, or do not know when the evidence was equivocal, conflicting, or insufficient.

A series of companion documents were created, adapted, or adopted to support the implementation of the guideline. These included a quick reference algorithm, a summary document, patient education sheets, and practice tools (a medication table, a headache history form, a patient diary, and a video demonstrating physical examination of the neck).

The draft guideline was reviewed by the Advisory Committee, a focus group of primary care physicians, and attendees at 2 Alberta physician conferences. The patient information sheets were reviewed by focus groups of patients and laypeople. The feedback was incorporated into the final documents, which were approved by the GDG in February 2012.

### Main message

The seed guidelines are listed in Table 1. The Alberta guideline’s 91 recommendations are organized into 6 sections. The full guideline and accompanying documents are available from the TOP website. The quick reference algorithm* information is provided in Figure 1 and Tables 2 to 4. Some general practice points are summarized in Box 1.

### Section 1: headache diagnosis and investigation

Box 2 presents important elements of the history for patients presenting with first-time headache or a change in headache pattern. Box 3 presents an approach to the physical examination specifically for primary care providers.

---

*The original quick reference algorithm is available in an easy-to-print format at www.cfp.ca. Go to the full text of the article online and click on CFPlus in the menu at the top right-hand side of the page.

### Table 1. Seed guidelines used to create the Guideline for Primary Care Management of Headache in Adults

<table>
<thead>
<tr>
<th>AUTHOR GROUP</th>
<th>DETAILS</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Headache Consortium, 2000</td>
<td>US: Neuroimaging in patients with nonacute headache; pharmacologic management of acute migraine attacks; pharmacologic prevention of migraine; behavioural and physical treatment of migraine</td>
</tr>
<tr>
<td>European Federation of Neurological Societies, 2009</td>
<td>Europe: Pharmacologic treatment of migraine</td>
</tr>
<tr>
<td>French Society for the Study of Migraine Headache, 2004</td>
<td>France: Diagnosis and management of migraine in adults and children</td>
</tr>
<tr>
<td>Scottish Intercollegiate Guidelines Network, 2008</td>
<td>UK: Diagnosis and management of headache in adults</td>
</tr>
<tr>
<td>European Federation of Neurological Societies, 2006</td>
<td>Europe: Treatment of cluster headache and other trigeminal autonomic cephalalgias</td>
</tr>
<tr>
<td>European Federation of Neurological Societies, 2010</td>
<td>Europe: Treatment of tension-type headache</td>
</tr>
</tbody>
</table>

UK—United Kingdom, US—United States.

Box 4 presents red flags and other potential indicators of secondary headache. Table 5 presents a simplified strategy for diagnosing primary headache disorders.

### Section 2: migraine

A comprehensive approach to migraine management is summarized in Box 5. Section 2 of the guideline contains recommendations for lifestyle management, acute treatment, prophylaxis, menstrual migraine, and migraine treatment during pregnancy. The full guideline provides a detailed medication table for migraine that includes available formulations, usual doses, relative and absolute contraindications, and adverse events. Boxes 6 and 7 show the indications and considerations for prescribing prophylactic drugs for migraine. Recommended medications are outlined in Table 2.

### Section 3: tension-type headache

This section contains recommendations on lifestyle, acute and prophylactic drug therapy, and management of tension-type headache during pregnancy. Recommended medications are outlined in Table 3.

### Section 4: medication-overuse headache

Migraine sufferers are particularly prone to developing medication-overuse headache. Recommendations for diagnosis and management of medication-overuse headache are shown in Boxes 8 and 9.
Figure 1. Quick reference algorithm from the Guideline for Primary Care Management of Headache in Adults

Red flags
Emergent (address immediately)
- Thunderclap onset
- Fever and meningismus
- Papilledema with focal signs or reduced LOC
- Acute glaucoma

Urgent (address within hours to days)
- Temporal arteritis
- Papilledema (WITHOUT focal signs or reduced LOC)
- Relevant systemic illness
- Elderly patient: new headache with cognitive change

Yes

Refer and investigate

Possible indicators of secondary headache
- Unexplained focal signs
- Atypical headaches
- Unusual headache precipitants
- Unusual aura symptoms
- Onset after age 50 y

- Aggravation by neck movement; abnormal neck examination findings (consider cervicogenic headache)
- Jaw symptoms; abnormal jaw examination findings (consider temporomandibular joint disorder)

Yes

Medication overuse
Migraine
Assess
- Ergots, triptans, combination analgesics, or codeine or other opioids ≥ 10 d/mo OR
- Acetaminophen or NSAIDs ≥ 15 d/mo
Manage
- Educate patient
- Consider prophylactic medication
- Provide an effective acute medication for severe attacks with limitations on frequency of use
- Gradual withdrawal of opioids if used, or combination analgesic with opioid or barbiturate
- Abrupt (or gradual) withdrawal of acetaminophen, NSAIDs, or triptans

Behavioural management
- Keep headache diary: record frequency, intensity, triggers, medication
- Adjust lifestyle factors: reduce caffeine, ensure regular exercise, avoid irregular or inadequate sleep or meals
- Develop stress management strategies: relaxation training, CBT, pacing activity, biofeedback

Tension-type headache
- Acute medications (Table 3)
- Monitor for medication overuse
- Prophylactic medication (Table 3) if disability despite acute medication

Cluster headache or another trigeminal autonomic cephalalgia
- Management primarily pharmacologic
- Acute medication (Table 4)
- Prophylactic medication (Table 4) if disability despite acute medication

Hemicrania continua
- Specialist referral

New daily persistent headache
- Specialist referral

Uncommon headache syndromes
All of
- Frequent headache
- Severe
- Brief (< 3 h per attack)
- Unilateral (always same side)
- Ipsilateral eye redness, tearing, or restlessness during attacks

All of
- Unilateral (always same side)
- Continuous
- Dramatically responsive to indomethacin
- Headache continuous since onset

Nausa
- Light sensitivity
- Interference with activities

Practice points:
- Migraine has been historically underdiagnosed
- Consider migraine diagnosis for recurring “sinus” headache

Headache with ≥ 2 of
- Nausea
- Light sensitivity
- Interference with activities

Tension-type headache
- Provide an effective acute medication for severe attacks with limitations on frequency of use
- Gradual withdrawal of opioids if used, or combination analgesic with opioid or barbiturate
- Abrupt (or gradual) withdrawal of acetaminophen, NSAIDs, or triptans

Hemicrania continua

CBT—cognitive behavioural therapy, LOC—level of consciousness, NSAID—nonsteroidal anti-inflammatory drug.
Adapted from Toward Optimized Practice.10
### Table 2. Migraine medications: A) Acute migraine medications. B) Prophylactic migraine medications.

<table>
<thead>
<tr>
<th>A)</th>
<th>ACUTE MEDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>First line</td>
<td>Ibuprofen 400 mg, ASA 1000 mg, naproxen sodium 500-550 mg, acetaminophen 1000 mg</td>
</tr>
<tr>
<td>Second line</td>
<td>Triptans: oral sumatriptan 100 mg, rizatriptan 10 mg, almotriptan 12.5 mg, zolmitriptan 2.5 mg, eletriptan 40 mg, frovatriptan 2.5 mg, naratriptan 2.5 mg</td>
</tr>
<tr>
<td></td>
<td>• Subcutaneous sumatriptan 6 mg if the patient is vomiting early in the attack. Consider for attacks resistant to oral triptans</td>
</tr>
<tr>
<td></td>
<td>• Oral wafer: rizatriptan 10 mg or zolmitriptan 2.5 mg if fluid ingestion worsens nausea</td>
</tr>
<tr>
<td></td>
<td>• Nasal spray: zolmitriptan 5 mg or sumatriptan 20 mg if patient is nauseated</td>
</tr>
<tr>
<td>Third line</td>
<td>Antiemetics: domperidone 10 mg or metoclopramide 10 mg for nausea</td>
</tr>
<tr>
<td>Fourth line</td>
<td>Naproxen sodium 500-550 mg in combination with a triptan</td>
</tr>
<tr>
<td></td>
<td>Fixed-dose combination analgesics (with codeine if necessary; not recommended for routine use)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B) PROPHYLACTIC MEDICATIONS</th>
<th>STARTING DOSE</th>
<th>TITRATION,* DAILY DOSE INCREASE</th>
<th>TARGET DOSE OR THERAPEUTIC RANGE†</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>First line</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• propranolol</td>
<td>20 mg twice daily</td>
<td>40 mg/wk</td>
<td>40-120 mg twice daily</td>
<td>Avoid in asthma</td>
</tr>
<tr>
<td>• metoprolol</td>
<td>50 mg twice daily</td>
<td>50 mg/wk</td>
<td>50-100 mg twice daily</td>
<td>Avoid in asthma</td>
</tr>
<tr>
<td>• nadolol</td>
<td>40 mg/d</td>
<td>20 mg/wk</td>
<td>80-160 mg/d</td>
<td>Avoid in asthma</td>
</tr>
<tr>
<td>• amitriptyline</td>
<td>10 mg at bedtime</td>
<td>10 mg/wk</td>
<td>10-100 mg at bedtime</td>
<td>Consider if patient has depression, anxiety, insomnia, or tension-type headache</td>
</tr>
<tr>
<td>• nortriptyline</td>
<td>10 mg at bedtime</td>
<td>10 mg/wk</td>
<td>10-100 mg at bedtime</td>
<td>Consider if patient has depression, anxiety, insomnia, or tension-type headache</td>
</tr>
<tr>
<td>Second line</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• topiramate</td>
<td>25 mg/d</td>
<td>25 mg/wk</td>
<td>50 mg twice daily</td>
<td>Consider as a first-line option if the patient is overweight</td>
</tr>
<tr>
<td>• candesartan</td>
<td>8 mg/d</td>
<td>8 mg/wk</td>
<td>16 mg/d</td>
<td>Few side effects; limited experience in prophylaxis</td>
</tr>
<tr>
<td>• gabapentin</td>
<td>300 mg/d</td>
<td>300 mg every 3-7 d</td>
<td>1200-1800 mg/d divided into 3 doses</td>
<td>Few drug interactions</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• divalproex</td>
<td>250 mg/d</td>
<td>250 mg/wk</td>
<td>750-1500 mg/d divided into 2 doses</td>
<td>Avoid in pregnancy or when pregnancy is possible</td>
</tr>
<tr>
<td>• pizotifen</td>
<td>0.5 mg/d</td>
<td>0.5 mg/wk</td>
<td>1-2 mg twice daily</td>
<td>Monitor for somnolence and weight gain</td>
</tr>
<tr>
<td>• onabotulinumtoxinA</td>
<td>155-195 units</td>
<td>No titration needed</td>
<td>155-195 units every 3 mo</td>
<td>For chronic migraine only (headache on ≥ 15 d/mo)</td>
</tr>
<tr>
<td>• flunarizine</td>
<td>5–10 mg at bedtime</td>
<td>No titration needed</td>
<td>10 mg at bedtime</td>
<td>Avoid in patients with depression</td>
</tr>
<tr>
<td>• venlafaxine</td>
<td>37.5 mg/d</td>
<td>37.5 mg/wk</td>
<td>150 mg/d</td>
<td>Consider for migraine in patients with depression</td>
</tr>
<tr>
<td>Over the counter</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• magnesium citrate</td>
<td>300 mg twice daily</td>
<td>No titration needed</td>
<td>300 mg twice daily</td>
<td>Effectiveness might be limited; few side effects</td>
</tr>
<tr>
<td>• riboflavin</td>
<td>400 mg/d</td>
<td>No titration needed</td>
<td>400 mg/d</td>
<td>Effectiveness might be limited; few side effects</td>
</tr>
<tr>
<td>• butterbur</td>
<td>75 mg twice daily</td>
<td>No titration needed</td>
<td>75 mg twice daily</td>
<td>Effectiveness might be limited; few side effects</td>
</tr>
<tr>
<td>• coenzyme Q10</td>
<td>100 mg 3 times daily</td>
<td>No titration needed</td>
<td>100 mg 3 times daily</td>
<td>Effectiveness might be limited; few side effects</td>
</tr>
</tbody>
</table>

ASA—acetylsalicylic acid.

*Dosage can be increased every 2 wk to avoid side effects. For most drugs, slowly increase to the target dose; a therapeutic trial requires several months. The expected outcome is reduction not elimination of attacks.

†If the target dose is not tolerated, try a lower dose. If the medication is effective and tolerated, continue it for at least 6 mo. If several preventive drugs fail, consider a specialist referral.

Adapted from Toward Optimized Practice.10
Section 5: cluster headache. Cluster headache is managed with a number of pharmacologic therapies. These can be initiated and monitored in primary care, but early specialist referral is recommended because this headache type is uncommon, disabling, and challenging to manage. Recommended medications are outlined in Table 4.10

Section 6: other headache disorders. This section of the guideline focuses on hemicrania continua, cervicogenic headache, and headache secondary to

Table 3. Medications for tension-type headache

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td></td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>400 mg</td>
</tr>
<tr>
<td>ASA</td>
<td>1000 mg</td>
</tr>
<tr>
<td>Naproxen sodium</td>
<td>500-550 mg</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>1000 mg</td>
</tr>
<tr>
<td>Prophylactic</td>
<td></td>
</tr>
<tr>
<td>First line</td>
<td></td>
</tr>
<tr>
<td>• amitriptyline</td>
<td>10-100 mg/d</td>
</tr>
<tr>
<td>• nortriptyline</td>
<td>10-100 mg/d</td>
</tr>
<tr>
<td>Second line</td>
<td></td>
</tr>
<tr>
<td>• mirtazapine</td>
<td>30 mg/d</td>
</tr>
<tr>
<td>• venlafaxine</td>
<td>150 mg/d</td>
</tr>
</tbody>
</table>
| ASA—acetylsalicylic acid. Adapted from Toward Optimized Practice.30

Table 4. Medications for cluster headache: Consider early specialist referral.

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous sumatriptan</td>
<td>6 mg</td>
</tr>
<tr>
<td>Intranasal zolmitriptan</td>
<td>5 mg</td>
</tr>
<tr>
<td>100% oxygen</td>
<td>12 L/min for 15 min through non-rebreathing mask</td>
</tr>
<tr>
<td>Prophylactic*</td>
<td></td>
</tr>
<tr>
<td>First line</td>
<td></td>
</tr>
<tr>
<td>• verapamil</td>
<td>240-480 mg/d (higher doses might be required)</td>
</tr>
<tr>
<td>Second line</td>
<td></td>
</tr>
<tr>
<td>• lithium</td>
<td>900-1200 mg/d</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>• topiramate</td>
<td>100-200 mg/d</td>
</tr>
<tr>
<td>• melatonin</td>
<td>Up to 10 mg/d</td>
</tr>
</tbody>
</table>

If the patient has more than 2 attacks daily, consider transitional therapy while verapamil is built up (eg, 60 mg of prednisone for 5 d, then reduced by 10 mg every 2 d until discontinued). Adapted from Toward Optimized Practice.30

Box 1. General practice points for managing primary headache in adults

The following are general practice points for the management of primary headache in adults:
• Rule out secondary headache when diagnosing a primary headache disorder
• Neuroimaging is not indicated in patients with recurrent headache with the clinical features of migraine, normal neurologic examination findings, and no red flags
• Neuroimaging, sinus or cervical spine x-ray scans, and electroencephalograms are not recommended for the routine assessment of patients with headache: history and physical and neurologic examination findings are usually sufficient to make a diagnosis of migraine or tension-type headache
• Migraine is by far the most common headache type in patients seeking help for headache from physicians
• Migraine is historically underdiagnosed and undertreated; many patients with migraine are not diagnosed with migraine when they consult a physician
• Migraine should be considered in patients with recurrent moderate or severe headaches and normal neurologic examination findings
• Patients consulting for bilateral headaches that interfere with their activities are likely to have migraine rather than tension-type headache and might require migraine-specific medication
• Consider a diagnosis of migraine in patients with a previous diagnosis of recurring “sinus” headache
• Medication overuse is considered to be present when patients with migraine or tension-type headache use combination analgesics, opioids, or triptans on ≥ 10 d/mo or acetaminophen or NSAIDs on ≥ 15 d/mo
• Comprehensive migraine therapy includes management of lifestyle factors and triggers, acute and prophylactic medications, and migraine self-management strategies
• A substantial number of people who might benefit from prophylactic therapy do not receive it

NSAID—nonsteroidal anti-inflammatory drug.

Box 2. Important elements of the headache history in patients presenting with headache for the first time or those with a change in headache pattern

Explore the following important elements of the headache history:
• Headache onset (thunderclap, head or neck trauma), previous attacks (progression of symptoms, duration of attacks < 3 hours, > 4 hours, continuous), days per month with headache
• Pain location (unilateral, bilateral, associated neck pain, etc)
• Headache-associated symptoms (nausea, vomiting, photophobia, conjunctival injection, rhinorrhea, etc)
• Relationship of headache attacks to precipitating factors (stress, posture, cough, exertion, straining, neck movement, jaw pain, etc)
• Headache severity and effect on work and family activities
• Acute and preventive medications tried, response, and side effects
• Presence of coexistent conditions that might influence treatment choice (insomnia, depression, anxiety, hypertension, asthma, and history of heart disease or stroke)

Based on expert opinion of the Guideline Development Group.
temporomandibular joint disorders. Treatment of these conditions will likely involve referral to an appropriately trained therapist or specialist.

**Box 3. Approach to the physical examination of a patient presenting with headache for the first time or with a change in headache pattern**

The physical examination should incorporate the following elements:
- Screening neurologic examination
  - General assessment of mental status
  - Cranial nerve examination
    - Funduscopic examination
    - Pupils, eye movements, visual fields, evaluation of facial movements for asymmetry and weakness
    - Assessment for unilateral limb weakness, reflex asymmetry, and coordination in the arms
    - Assessment of gait, including heel-toe walking (tandem gait)
- Neck examination
  - Posture, range of motion, and palpation for muscle tender points
- Blood pressure measurement
  - If indicated by other neurologic symptoms or signs on screening examination, a focused neurologic examination (eg, lower cranial nerve examination in a patient with dysarthria, or plantar responses in a patient with reflex asymmetry)
- If indicated by associated jaw complaints, an examination for temporomandibular disorders
  - Assessment of jaw opening
  - Palpation of muscles of mastication for tender points

Based on the Scottish Intercollegiate Guidelines Network guideline and expert opinion of the Guideline Development Group.

**Box 4. Red flags and other potential indicators of secondary headache: Appropriate referral or investigation should be considered.**

- Red flags: emergent (address immediately)
  - Thunderclap onset
  - Fever and meningismus
  - Papilledema with focal signs or reduced level of consciousness
  - Acute glaucoma
- Red flags: urgent (address within hours to days)
  - Temporal arteritis
  - Papilledema without focal signs or reduced level of consciousness
  - Relevant systemic illness
  - Elderly patient: new headache with cognitive change
- Other possible indicators of secondary headache (less urgent)
  - Unexplained focal signs
  - Atypical headaches (not consistent with migraine or tension-type headache)
  - Unusual headache precipitants
  - Unusual aura symptoms
  - Onset after age 50 y
  - Aggravation by neck movement; abnormal neck examination findings (consider cervicogenic headache)
  - Jaw symptoms; abnormal jaw examination findings (consider temporomandibular joint disorder)

Based on the Scottish Intercollegiate Guidelines Network guideline and expert opinion of the Guideline Development Group.

**Implementation and update plans**

The guideline has been disseminated through presentations and workshops at provincial, regional, and national conferences. It is also listed in the CMA Infobase, where it was among the 10 most downloaded guidelines for nearly 6 months. It also appears

**Box 5. Comprehensive migraine management**

Consider the following when managing patients with migraine:
- Pay attention to lifestyle and specific migraine triggers in order to reduce the frequency of attacks. Lifestyle factors to avoid include the following:
  - Irregular or skipped meals
  - Irregular or too little sleep
  - A stressful lifestyle
  - Excessive caffeine consumption
  - Lack of exercise
  - Obesity
- Use acute pharmacologic therapy for individual attacks
- Use prophylactic pharmacologic therapy, when indicated, to reduce attack frequency
- Use nonpharmacologic therapies
- Evaluate and treat coexistent medical and psychiatric disorders
- Encourage patients to participate actively in their treatment and to employ self-management principles:
  - Self-monitoring to identify factors influencing migraine
  - Managing migraine triggers effectively
  - Pacing activity to avoid triggering or exacerbating migraine
  - Maintaining a lifestyle that does not worsen migraine
  - Practising relaxation techniques
  - Maintaining good sleep hygiene
  - Developing stress management skills
  - Improving communication skills to talk effectively about pain with family and others
  - Using acute and prophylactic medication appropriately

Based on expert opinion of the Guideline Development Group.

**Box 6. Pharmacologic prophylaxis for migraine**

Prophylactic medication is indicated in the following circumstances:
- Recurrent migraine attacks are causing considerable disability despite optimal acute drug therapy
- Frequency of acute medication use is approaching levels that place the patient at risk of medication-overuse headache
  - Acute medications are used on ≥ 15 d/mo for acetaminophen, ergots, NSAIDs, and combination analgesics
  - Acute medications are used on ≥ 15 d/mo for acetaminophen and NSAIDs
- Recurrent attacks with prolonged aura are occurring (hemiplegic migraine, basilar-type migraine, etc.)
- Contraindications to acute migraine medications are making symptomatic treatment of migraine attacks difficult
  - NSAID—nonsteroidal anti-inflammatory drug

Based on expert opinion of the Guideline Development Group.
on the Michael G. DeGroote National Pain Centre website and is listed by the US National Guideline Clearing House. A pilot project is under way at the University of Calgary in Alberta to present the headache guideline using interactive webinars.

The evidence base for the Alberta CPG will be assessed annually and will be updated when new evidence is found that changes the recommendations.

Limitations
The guideline adaptation process precluded an in-depth analysis of the validity or a formal assessment of the strength and quality of the underlying empirical evidence, which made categorizing the strength and type of recommendations problematic. To counter this problem, standardized definitions were constructed for the types of recommendations made in the Alberta CPG (eg, what constituted a do or do not do recommendation) from the overlapping evidence-rating scales used by the seed guidelines, and designations were used (eg, SR for systematic review) to maintain a link to the evidence type referenced by the seed guidelines in support of their recommendations.

The lack of high-quality scientific evidence for headache investigations, diagnosis, red flags, and specialist referral meant that many recommendations in these areas relied on the opinions of the GDG or the experts who developed the seed guidelines. However, these

<table>
<thead>
<tr>
<th>Table 5. Diagnosing primary headache syndromes</th>
</tr>
</thead>
<tbody>
<tr>
<td>DESCRIPTION</td>
</tr>
<tr>
<td>------------------------------------------------</td>
</tr>
</tbody>
</table>
| Patients with recurrent headache attacks and normal neurologic examination findings (in some patients other clinical symptoms might also need to be considered)* | • Diagnose migraine without aura (migraine with aura if an aura is present) if they have at least 2 of the following:
  - nausea during the attack
  - light sensitivity during the attack
  - some of the attacks interfere with their activities
  • Diagnose episodic tension-type headache† if headache attacks are not associated with nausea, and have at least 2 of the following:
  - bilateral headache
  - nonpulsating pain
  - mild to moderate intensity
  - headache is not worsened by activity
  • Diagnose cluster headache or another trigeminal autonomic cephalalgia if headache attacks meet all the following criteria:
  - frequent
  - severe
  - brief (duration < 3 h)
  - unilateral
  - ipsilateral conjunctival injection, tearing, or restlessness during the attacks (ipsilateral ptosis or miosis might be present on examination). Neurologist referral recommended |
| Patients with headache on ≥15 d/mo for >3 mo and with normal neurologic examination findings‡ | • Diagnose chronic migraine if headaches meet migraine diagnostic criteria (above) or are quickly aborted by migraine-specific medications (triptans or ergots) on ≥8 d/mo
  - Chronic migraine with medication overuse if the patient uses ergots, triptans, opioids, or combination analgesics on ≥10 d/mo or uses plain acetaminophen or NSAIDs on ≥15 d/mo
  - Chronic migraine without medication overuse if patients do not have medication overuse as defined above
  • Diagnose chronic tension-type headache if headaches meet episodic tension-type headache diagnostic criteria (above), except mild nausea might be present |
| Patients with continuous daily headache for >3 mo with normal neurologic examination findings§ | • Diagnose hemicrania continua|| (neurologist referral recommended) if the headache
  - is strictly unilateral
  - is always on the same side of the head (ptosis or miosis might be present on examination)
  - responds dramatically to indomethacin
  • Diagnose new daily persistent headache|| if the headache is unremitting since its onset. It is important to consider secondary headaches in these patients. Neurologist referral recommended |

NSAID—nonsteroidal anti-inflammatory drug.
*Modified from the International Classification of Headache Disorders; data from Lipton et al; and based on expert opinion of the Guideline Development Group.
†If patients do not meet migraine diagnostic criteria.
‡Modified from the International Classification of Headache Disorders and based on expert opinion of the Guideline Development Group.
§Modified from the International Classification of Headache Disorders and based on expert opinion of the Guideline Development Group.
||This less common headache syndrome should be considered in patients with continuous headache.
issues were overcome by using credible seed guidelines, scrupulously listing the evidence type and source for all recommendations, and clearly documenting the subjective contextualization process.

Box 7. Pharmacologic prophylaxis for migraine

Consider the following when prescribing prophylactic medication:

- Educate patients on the need to take the medication daily and according to the prescribed frequency and dosage
- Ensure that patients have realistic expectations as to what the likely benefits of pharmacologic prophylaxis will be:
  - Headache attacks will likely not be abolished completely
  - A reduction in headache frequency of 50% is usually considered worthwhile and successful
  - It might take 4–8 wk for substantial benefit to occur
- If the prophylactic drug provides substantial benefit in the first 2 mo of therapy, this benefit might increase further over several additional months of therapy
- Evaluate the effectiveness of therapy using patient diaries that record headache frequency, drug use, and disability levels
- For most prophylactic drugs, initiate therapy with a low dose and increase the dosage gradually to minimize side effects
- Increase the dose until the drug proves effective, until dose-limiting side effects occur, or until a target dose is reached
- Provide an adequate drug trial. Unless side effects mandate discontinuation, continue the prophylactic drug for at least 6–8 wk after dose titration is completed
- Because migraine attack tendency fluctuates over time, consider gradual discontinuation of the drug for many patients after 6 to 12 mo of successful prophylactic therapy, but preventive medications can be continued for much longer in patients who have experienced substantial migraine-related disability

Box 8. Diagnosis of medication-overuse headache

Consider the following in the diagnosis of medication-overuse headache:

- Consider a diagnosis of medication overuse headache in patients with headache on ≥15 d/mo and assess patients for possible medication overuse (use of triptans, ergots, combination analgesics, or opioid-containing medications on ≥10 d/mo, use of acetaminophen or NSAIDs on ≥15 d/mo)
- When medication-overuse headache is suspected, the patient should also be evaluated for the presence of the following:
  - Psychiatric comorbidities (depression and anxiety); these might need to be considered in planning an overall treatment strategy
  - Psychological and physical drug dependence
  - Use of inappropriate coping strategies. Rather than relying on medication as a main coping strategy, patients with suspected medication overuse might benefit from training in and development of more adaptive self-management strategies (eg, identification and management of controllable headache triggers, relaxation exercises, effective stress management skills, and activity pacing)
- Headache diaries that record acute medication intake are important in the prevention and treatment of medication-overuse headache

Box 9. Management of medication-overuse headache

Treatment plans for patients with medication-overuse headache should include the following:

- Patient education. Patients need to understand that:
  - Acute medication overuse can increase headache frequency
  - When medication overuse is stopped, headache might worsen temporarily and other withdrawal symptoms might occur
  - Many patients will experience a long-term reduction in headache frequency after medication overuse is stopped
- A strategy for cessation of medication overuse
  - Abrupt withdrawal should be advised for patients with suspected medication-overuse headache caused by simple analgesics (acetaminophen, NSAIDs) or triptans; however, gradual withdrawal is also an option
  - Gradual withdrawal should be advised for patients with suspected medication-overuse headache caused by opioids and opioid-containing analgesics
- Provision of a prophylactic medication while medication overuse is stopped. While many prophylactic agents are used (tricyclics, β-blockers, etc), drugs with the best evidence for efficacy in chronic migraine with medication overuse are onabotulinumtoxinA, 155 units to 195 units injected at intervals of 3 mo by clinicians experienced in its use for headache
- Topiramate with slow titration to a target dose of 100 mg/d
- A strategy for the treatment of remaining severe headache attacks with limitations on frequency of use (eg, a triptan for patients with analgesic overuse, dihydroergotamine for patients with triptan overuse, etc)
- Patient follow-up and support

Adaptation processes are limited by the time lag between the publication of primary studies and their incorporation into guidelines, which means that recently published evidence was not necessarily incorporated into the Alberta CPG and that not all of the treatment options available were covered by the seed guidelines. To help offset this, the research team updated searches regularly throughout the Alberta guideline adaptation process.

There was debate among the GDG members about incorporating newly emerging headache treatments that were not identified in the seed guidelines. A conservative approach was adopted whereby a recommendation for an emerging intervention was created only if it had been assessed in a systematic review.

None of the seed guidelines included formal economic evaluations or cost analyses, nor did they discuss the economic implications of their recommendations. Owing to time and resource constraints, a formal cost analysis or economic evaluation of the effect of the Alberta CPG was not conducted. However, any statements on economic aspects made by the seed guidelines were noted in the accompanying background document.11
Conclusion

The format and brevity of the Guideline for Primary Care Management of Headache in Adults reflects its intent—to provide Canadian primary care providers across multiple disciplines with a comprehensive suite of resources for assessing and managing headaches in adults. A guideline summary and algorithm, as well as practice tools and patient information sheets, are provided to support comprehensive headache management that emphasizes patient engagement and self-management, as well as evidence-informed interventions.

Dr Becker is Professor in the Department of Clinical Neurosciences at the University of Calgary in Alberta. Dr Findlay is Clinical Assistant Professor in the Department of Family Medicine at the University of Calgary. Drs Moga and Scott are Research Associates in Health Technology Assessment at the Institute of Health Economics in Edmonton, Alta. Ms Harstall is Director of Health Technology Assessment at the Institute of Health Economics. Dr Taenzner is Adjunct Clinical Assistant Professor in the Faculty of Medicine at the University of Calgary.

Contributors

All authors contributed to the literature review and interpretation, and to preparing the manuscript for submission.

Acknowledgment

We thank the members of the Ambassador Program Guideline Development Group, the Advisory Committee, and the Steering Committee for their commitment and hard work. We also thank all of the organizations that provided support during the guideline development process, particularly Toward Optimized Practice for guidance in the final stages of the guideline process and for hosting the completed guideline online. Special thanks to Dr James N. Scott (radiology) and Dr Robert Ashforth (radiology) for their invaluable contributions to the diagnostic imaging components of the guideline. We also thank Ms Wendy McIndoo for administrative assistance and Ms Liz Dennett and Ms Dagmara Chojecki for information services support. Funding for this initiative was provided by Alberta Health. The views expressed herein do not necessarily represent the official policy of Alberta Health.

Competing interests

Dr Becker served on medical advisory boards for AGA Medical, Allergan, Merck, and Pfizer, received speaker's honoraria from Allergan, Merck, Pfizer, Serono, and Teva, and received research support as part of multicenter clinical trials (served as local principal investigator) from AGA Medical, Allergan, Medtronic, and Merck. However, these interests had no influence on the design, data analysis, formulation, or content of the guideline. None of the other authors has any conflict of interest to declare.

Correspondence

Dr Werner J. Becker; e-mail whecker@ucalgary.ca

References